{"count": 27, "results": [{"_id": "39694747", "pmid": 39694747, "title": "Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial.", "journal": "Eur J Intern Med", "authors": ["Olsen E", "Jamerson K", "Schmieder RE", "Søraas CL", "Mariampillai JE", "Mancia G", "Kjeldsen SE", "Heimark S", "Mehlum MH", "Liestøl K", "Larstorp ACK", "Halvorsen LV", "Høieggen A", "Burnier M", "Rostrup M", "Julius S", "Weber MA"], "date": "2024-12-17T00:00:00Z", "doi": "10.1016/j.ejim.2024.12.021", "meta_date_publication": "2024 Dec 17", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50260.22, "text_hl": "Effects of @CHEMICAL_Valsartan @CHEMICAL_MESH:D000068756 @@@valsartan@@@ vs @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ and achieved lower blood pressure on the incidence of @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@end-stage kidney disease@@@: The VALUE Trial.", "citations": {"NLM": "Olsen E, Jamerson K, Schmieder RE, Søraas CL, Mariampillai JE, Mancia G, Kjeldsen SE, Heimark S, Mehlum MH, Liestøl K, Larstorp ACK, Halvorsen LV, Høieggen A, Burnier M, Rostrup M, Julius S, Weber MA. Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial. Eur J Intern Med. 2024 Dec 17;():. PMID: 39694747", "BibTeX": "@article{39694747, title={Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial.}, author={Olsen E and Jamerson K and Schmieder RE and Søraas CL and Mariampillai JE and Mancia G and Kjeldsen SE and Heimark S and Mehlum MH and Liestøl K and Larstorp ACK and Halvorsen LV and Høieggen A and Burnier M and Rostrup M and Julius S and Weber MA}, journal={Eur J Intern Med}}"}}, {"_id": "34470455", "pmid": 34470455, "title": "Strange coincidence in the gut: pseudomelanosis duodeni diagnosed by capsule endoscopy and active bleeding due to angiodysplasia.", "journal": "Rev Esp Enferm Dig", "authors": ["Martín-Cardona A", "Aceituno M", "Arau B", "Fernández-Urién I"], "date": "2022-02-01T00:00:00Z", "doi": "10.17235/reed.2021.8254/2021", "meta_date_publication": "2022 Feb", "meta_volume": "114", "meta_issue": "2", "meta_pages": "120-121", "score": 50239.508, "text_hl": "We present the case of an 82-year-old male with a medical history of @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@, @DISEASE_Dyslipidemias @DISEASE_MESH:D050171 @@@dyslipidemia@@@, @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes mellitus@@@, @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@chronic renal failure@@@, @DISEASE_Myocardial_Ischemia @DISEASE_MESH:D017202 @@@ischemic heart disease@@@ and @DISEASE_Anemia_Iron_Deficiency @DISEASE_MESH:D018798 @@@iron deficiency anemia@@@. ", "citations": {"NLM": "Martín-Cardona A, Aceituno M, Arau B, Fernández-Urién I. Strange coincidence in the gut: pseudomelanosis duodeni diagnosed by capsule endoscopy and active bleeding due to angiodysplasia. Rev Esp Enferm Dig. 2022 Feb;114(2):120-121. PMID: 34470455", "BibTeX": "@article{34470455, title={Strange coincidence in the gut: pseudomelanosis duodeni diagnosed by capsule endoscopy and active bleeding due to angiodysplasia.}, author={Martín-Cardona A and Aceituno M and Arau B and Fernández-Urién I}, journal={Rev Esp Enferm Dig}, volume={114}, number={2}, pages={120-121}}"}}, {"_id": "23516009", "pmid": 23516009, "title": "Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report.", "journal": "Afr Health Sci", "authors": ["Aldemir NM", "Begenik H", "Emre H", "Erdur FM", "Soyoral Y"], "date": "2012-12-01T00:00:00Z", "doi": "10.4314/ahs.v12i4.30", "meta_date_publication": "2012 Dec", "meta_volume": "12", "meta_issue": "4", "meta_pages": "576-8", "score": 50071.08, "text_hl": "@<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@Amlodipine@@@-induced @DISEASE_Gingival_Hyperplasia @DISEASE_MESH:D005885 @@@gingival hyperplasia@@@ in @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@chronic renal failure@@@: a case report.", "citations": {"NLM": "Aldemir NM, Begenik H, Emre H, Erdur FM, Soyoral Y. Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report. Afr Health Sci. 2012 Dec;12(4):576-8. PMID: 23516009", "BibTeX": "@article{23516009, title={Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report.}, author={Aldemir NM and Begenik H and Emre H and Erdur FM and Soyoral Y}, journal={Afr Health Sci}, volume={12}, number={4}, pages={576-8}}"}}, {"_id": "19167800", "pmid": 19167800, "title": "Association between peritoneal dialysate effluent leukocytosis and amlodipine besylate.", "journal": "Am J Kidney Dis", "authors": ["Lee F", "Yu MC"], "date": "2009-03-01T00:00:00Z", "doi": "10.1053/j.ajkd.2008.10.040", "meta_date_publication": "2009 Mar", "meta_volume": "53", "meta_issue": "3", "meta_pages": "e1-3", "score": 50063.066, "text_hl": "This study describes a girl aged 2 years 9 months with @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@end-stage renal disease@@@ resulting from crescent @DISEASE_Glomerulonephritis @DISEASE_MESH:D005921 @@@glomerulonephritis@@@ and severe @DISEASE_Nephritis_Interstitial @DISEASE_MESH:D009395 @@@interstitial nephritis@@@ who developed @DISEASE_Leukocytosis @DISEASE_MESH:D007964 @@@leukocytosis@@@ with a predominance of lymphocytes in the dialysate effluent, and in whom the effluent cell count normalized 1 week after discontinuation of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine besylate@@@ therapy. ", "citations": {"NLM": "Lee F, Yu MC. Association between peritoneal dialysate effluent leukocytosis and amlodipine besylate. Am J Kidney Dis. 2009 Mar;53(3):e1-3. PMID: 19167800", "BibTeX": "@article{19167800, title={Association between peritoneal dialysate effluent leukocytosis and amlodipine besylate.}, author={Lee F and Yu MC}, journal={Am J Kidney Dis}, volume={53}, number={3}, pages={e1-3}}"}}, {"_id": "17063175", "pmid": 17063175, "title": "Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.", "journal": "Kidney Int", "authors": ["Aslam S", "Santha T", "Leone A", "Wilcox C"], "date": "2006-12-01T00:00:00Z", "doi": "10.1038/sj.ki.5001983", "meta_date_publication": "2006 Dec", "meta_volume": "70", "meta_issue": "12", "meta_pages": "2109-15", "score": 50061.902, "text_hl": "Effects of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ and @CHEMICAL_Valsartan @CHEMICAL_MESH:D000068756 @@@valsartan@@@ on oxidative stress and plasma methylarginines in @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@end-stage renal disease@@@ @SPECIES_9606 @@@patients@@@ on hemodialysis.", "citations": {"NLM": "Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int. 2006 Dec;70(12):2109-15. PMID: 17063175", "BibTeX": "@article{17063175, title={Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.}, author={Aslam S and Santha T and Leone A and Wilcox C}, journal={Kidney Int}, volume={70}, number={12}, pages={2109-15}}"}}, {"_id": "8389563", "pmid": 8389563, "title": "Comparative renal hemodynamic effects of lisinopril, verapamil, and amlodipine in patients with chronic renal failure.", "journal": "Am J Hypertens", "authors": ["August P", "Lenz T", "Laragh JH"], "date": "1993-04-01T00:00:00Z", "doi": "10.1093/ajh/6.4s.148s", "meta_date_publication": "1993 Apr", "meta_volume": "6", "meta_issue": "4", "meta_pages": "148S-154S", "score": 50061.52, "text_hl": "Comparative renal hemodynamic effects of @CHEMICAL_Lisinopril @CHEMICAL_MESH:D017706 @@@lisinopril@@@, @CHEMICAL_Verapamil @CHEMICAL_MESH:D014700 @@@verapamil@@@, and @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@chronic renal failure@@@.", "citations": {"NLM": "August P, Lenz T, Laragh JH. Comparative renal hemodynamic effects of lisinopril, verapamil, and amlodipine in patients with chronic renal failure. Am J Hypertens. 1993 Apr;6(4):148S-154S. PMID: 8389563", "BibTeX": "@article{8389563, title={Comparative renal hemodynamic effects of lisinopril, verapamil, and amlodipine in patients with chronic renal failure.}, author={August P and Lenz T and Laragh JH}, journal={Am J Hypertens}, volume={6}, number={4}, pages={148S-154S}}"}}, {"_id": "12508961", "pmid": 12508961, "title": "Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study.", "journal": "Clin Nephrol", "authors": ["Yildiz A", "Hursit M", "Celik AV", "Kayacan SM", "Yazici H", "Akkaya V", "Gürol AO", "Karsidag K"], "date": "2002-12-01T00:00:00Z", "doi": "10.5414/cnp58405", "meta_date_publication": "2002 Dec", "meta_volume": "58", "meta_issue": "6", "meta_pages": "405-10", "score": 50058.707, "text_hl": "@CHEMICAL_Doxazosin @CHEMICAL_MESH:D017292 @@@Doxazosin@@@, but not @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ decreases @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin resistance@@@ in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@chronic renal failure@@@: a prospective, randomized-controlled study.", "citations": {"NLM": "Yildiz A, Hursit M, Celik AV, Kayacan SM, Yazici H, Akkaya V, Gürol AO, Karsidag K. Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. Clin Nephrol. 2002 Dec;58(6):405-10. PMID: 12508961", "BibTeX": "@article{12508961, title={Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study.}, author={Yildiz A and Hursit M and Celik AV and Kayacan SM and Yazici H and Akkaya V and Gürol AO and Karsidag K}, journal={Clin Nephrol}, volume={58}, number={6}, pages={405-10}}"}}, {"_id": "15897360", "pmid": 15897360, "title": "Blood pressure control, drug therapy, and kidney disease.", "journal": "Hypertension", "authors": ["Contreras G", "Greene T", "Agodoa LY", "Cheek D", "Junco G", "Dowie D", "Lash J", "Lipkowitz M", "Miller ER 3rd", "Ojo A", "Sika M", "Wilkening B", "Toto RD", "African American Study of Kidney Disease and Hypertension Study Group Investigators"], "date": "2005-07-01T00:00:00Z", "doi": "10.1161/01.HYP.0000166746.04472.60", "meta_date_publication": "2005 Jul", "meta_volume": "46", "meta_issue": "1", "meta_pages": "44-50", "score": 50057.35, "text_hl": "The low BP goal was associated with reduced risk of @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@ESRD@@@ or @DISEASE_Death @DISEASE_MESH:D003643 @@@death@@@ (risk reduction 51%; 95% confidence interval, 13% to 73%) and @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@ESRD@@@ (54%; 8% to 77%) for @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ @SPECIES_9606 @@@patients@@@, but not for @SPECIES_9606 @@@patients@@@ assigned to the other drug groups. ", "citations": {"NLM": "Contreras G, Greene T, Agodoa LY, Cheek D, Junco G, Dowie D, Lash J, Lipkowitz M, Miller ER 3rd, Ojo A, Sika M, Wilkening B, Toto RD, African American Study of Kidney Disease and Hypertension Study Group Investigators. Blood pressure control, drug therapy, and kidney disease. Hypertension. 2005 Jul;46(1):44-50. PMID: 15897360", "BibTeX": "@article{15897360, title={Blood pressure control, drug therapy, and kidney disease.}, author={Contreras G and Greene T and Agodoa LY and Cheek D and Junco G and Dowie D and Lash J and Lipkowitz M and Miller ER 3rd and Ojo A and Sika M and Wilkening B and Toto RD and African American Study of Kidney Disease and Hypertension Study Group Investigators}, journal={Hypertension}, volume={46}, number={1}, pages={44-50}}"}}, {"_id": "13679481", "pmid": 13679481, "title": "An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.", "journal": "Nephrol Dial Transplant", "authors": ["Palmer AJ", "Annemans L", "Roze S", "Lamotte M", "Rodby RA", "Cordonnier DJ"], "date": "2003-10-01T00:00:00Z", "doi": "10.1093/ndt/gfg232", "meta_date_publication": "2003 Oct", "meta_volume": "18", "meta_issue": "10", "meta_pages": "2059-66", "score": 50057.203, "text_hl": "RESULTS: Onset of @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@ESRD@@@ was delayed with @CHEMICAL_Irbesartan @CHEMICAL_MESH:D000077405 @@@irbesartan@@@ by 1.41 and 1.35 years vs @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ and control, respectively. ", "citations": {"NLM": "Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant. 2003 Oct;18(10):2059-66. PMID: 13679481", "BibTeX": "@article{13679481, title={An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.}, author={Palmer AJ and Annemans L and Roze S and Lamotte M and Rodby RA and Cordonnier DJ}, journal={Nephrol Dial Transplant}, volume={18}, number={10}, pages={2059-66}}"}}, {"_id": "11867945", "pmid": 11867945, "title": "Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.", "journal": "Nephron", "authors": ["Shibasaki Y", "Masaki H", "Nishiue T", "Nishikawa M", "Matsubara H", "Iwasaka T"], "date": "2002-03-01T00:00:00Z", "doi": "10.1159/000049060", "meta_date_publication": "2002 Mar", "meta_volume": "90", "meta_issue": "3", "meta_pages": "256-61", "score": 50056.87, "text_hl": "In contrast, the plasma angiotension II concentration did not change with @CHEMICAL_Enalapril @CHEMICAL_MESH:D004656 @@@enalapril@@@ and only increased 2-fold with @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@. Thus, the present study indicates that @CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@losartan@@@ more effectively regresses @DISEASE_Hypertrophy_Left_Ventricular @DISEASE_MESH:D017379 @@@LVH@@@ in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@ESRD@@@ than do @CHEMICAL_Enalapril @CHEMICAL_MESH:D004656 @@@enalapril@@@ and @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ despite a comparable depressor effect between the three drugs.", "citations": {"NLM": "Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron. 2002 Mar;90(3):256-61. PMID: 11867945", "BibTeX": "@article{11867945, title={Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.}, author={Shibasaki Y and Masaki H and Nishiue T and Nishikawa M and Matsubara H and Iwasaka T}, journal={Nephron}, volume={90}, number={3}, pages={256-61}}"}}]}